The company focuses on engineered tumor infiltrating lymphocyte (TIL) cell therapies using its proprietary Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead candidate AXN-2510/IMM2510 is in Phase 1b/2 trials for advanced/metastatic non-small cell lung cancer, with additional Phase 1 studies in China exploring multiple solid tumor types.
Cyborg Score Rationale
The company is currently unprofitable and not forecast to become profitable over the next 3 years. The stock has significantly underperformed both its industry and the broader market over the past year. With a market cap of approximately $44.8M and negative EPS, the company faces substantial execution risk as a clinical-stage biotech with limited resources.
Top Insights
Proprietary CoStAR platform targeting folate receptor alpha for multiple solid tumors including ovarian, uterine, and lung cancers
Market cap severely compressed to $44.8M, indicating significant market skepticism
Stock exhibits high volatility (16% weekly) compared to broader market
Lean operational structure with only 14 employees suggests outsourced development model
Named Competitors
Kymriah — CAR-T cell therapy for hematologic malignancies
Yescarta — CAR-T cell therapy for lymphomas
Afamitresgene Autoleucel — TIL cell therapy for melanoma